The role of mitochondria-derived peptides in cardiovascular disease: Recent updates.
Yang. Yingxi Y; Gao. Huijuan H; Zhou. Huan H; Liu. Qi Q; Qi. Zhongwen Z; Zhang. Ying Y; Zhang. Junping J
Key Findings
- Humanin and related peptides protect mitochondria and cells under stress
- They are linked to better outcomes in heart injury and lower inflammation
- They are being studied as new biomarkers or drug targets for cardiovascular disease
Practical Outcomes
- At this stage you can’t supplement Humanin with a proven protocol, but supporting overall mitochondrial health (e.g., exercise, good sleep, nutrient precursors) may naturally boost these peptides while you watch for future clinical trials.
Summary
This review says tiny proteins made by mitochondria, like Humanin, help protect heart cells and may lower heart disease risk, but the science is still early and no clear dosing advice exists.
Abstract
Mitochondria-derived peptides (MDPs) are a series of peptides encoded by mitochondrial DNA, and have similar functions to mitochondria. At present there are three types of MDPs that have been found, including Humanin, MOTS-c and SHLP1-6. They are new metabolic regulators of human body, and play a cytoprotective role in maintaining mitochondrial function and cell viability under pressure. Increasingly researchers have demonstrated that MDPs have proved effects on cell survival, metabolism, response to stressors, and inflammation in vivo and vitro. Recently with the advance of research, it have shown that MDPs have significant effects on the development of cardiovascular diseases (CVD). In this review, we will cover the relationships of MDPs with cardiovascular risk factors, myocardial ischemia, reperfusion injury, myocardial fibrosis, and coronary microcirculatory dysfunction, and also their possible pathogenic mechanisms. MDPs are considered to be novel biomarkers or therapeutic targets for CVD.
Study Information
pubmed
2019
2019-06-08T00:00:00.000Z
10.1016/j.biopha.2019.109075
62
102